Hence, considering that systemic injections of IL-22 increase the risk of hepatocellular carcinoma in patients with CLD (104–106), altering the gut microbiota to regulate the immune cells that produce IL-22 may offer a more viable option for liver injury therapeutic interventions. The gene discussed is IL22; the disease is hepatocellular carcinoma.